Glycyrrhiza/phosphatidylcholine - Pharmstandard

Drug Profile

Glycyrrhiza/phosphatidylcholine - Pharmstandard

Alternative Names: Glycyrrhiza/phospholipids-Pharmstandard; Glycyrrhizic acid/phosphatidylcholine; Phosphatidylcholine/glycyrrhiza; Phosphatidylcholine/glycyrrhizic acid; Phosphogliv; Phospholipids/glycyrrhiza-Pharmstandard

Latest Information Update: 31 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
  • Developer Pharmstandard
  • Class Anti-inflammatories; Antivirals; Hepatoprotectants; Phosphatidylcholines; Phospholipids; Triterpenes
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Lipid metabolism disorders; Liver disorders

Most Recent Events

  • 31 Dec 2005 Launched for Lipid metabolism disorders in Russia during 2005 (PO)
  • 31 Dec 2005 Launched for Liver disorders in Russia during 2005 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top